Skip to main content
News > News > National Science Foundation Awards Bacterial Robotics A Grant To Develop Tumor Treatment Product

National Science Foundation Awards Bacterial Robotics A Grant To Develop Tumor Treatment Product

SBIR Phase 1:  A Novel Approach to Cholesteatoma Treatment

CINCINNATI, OH, USA –December 9, 2013 – Bacterial Robotics, a life science firm developing microscopic BactoBots™ announced the receipt of a Small Business Innovation Research (SBIR) grant award from the National Science Foundation (NSF).

The award is effective January 1, 2014 and expires June 30, 2014.

The purpose of the grant is to continue the development of a BactoBot™ that selectively targets and kills skull-based cholesteatoma tumors.  The BactoBot, code named AuriBot™, is being developed as a replacement or augmentation to invasive neurotology surgeries currently used to remove cholesteatoma.

An uncomplicated cholesteatoma surgery typically costs $40,000.00 USD.  Approximately 150,000 if these surgeries are conducted annually in the USA.  The resulting USA market for cholesteatoma surgery is over $600,000,000.00 per year. The global market is significantly larger.

Ravi Samy, MD, FACS, Bacterial Robotics Chief Medical Officer, continued, “Skull-based tumors destroy hearing and lead to death.  It is not only a question of morbidity and mortality; it is a quality of life consideration.  This NSF award is an important step toward a unique intervention product and technique.”

Dr. Samy is Director of the Neurotology Fellowship at the University of Cincinnati, College of Medicine as well as the Director of the Adult Cochlear Implant Program and an Associate Professor of the Dept. of Otolaryngology.

Another unfortunate aspect of cholesteatoma is a high recurrence rate of nearly 70% after surgery.

The BactoBot cholesteatoma tumor eradication coupled with complimentary products like cochlear implants, could be less expensive, have less risk, lower rates of recurrence, and be a quality of life enhancement regimen for patients.

Bacterial Robotics CEO, Jason E. Barkeloo, finished, “The goal of developing a BactoBot that can selectively seek and destroy tumors without cutting could place us on a pathway to a transformative surgical product.  Such a new technique could bring medical intervention to people around the world without access to highly trained surgeons and expensive operating facilities.”

Upon the completion of the AuriBot development, the resulting intellectual property and knowledge will be licensed exclusively to Auricle Solutions, the Bacterial Robotics subsidiary.  Auricle Solutions will be responsible to further the development of the AuriBot technology with strategic medical device partners.

Bacterial Robotics similarly partnered its Pilus Energy subsidiary with Tauriga Sciences, Inc. (OTCQB: TAUG) on October 29, 2013.  Subsequently, on November 25th, 2013, Tauriga Sciences announced a Definitive Agreement to Acquire Pilus Energy from Bacterial Robotics (http://globenewswire.com/news-release/2013/11/25/592275/10059395/en/Tauriga-Sciences-Inc-Signs-Definitive-Agreement-to-Acquire-Synthetic-Biology-Developer-Pilus-Energy-LLC.html).

VIEW PRESS RELEASE AS A .PDF

About Auricle Solutions

Auricle Solutions is the Bacterial Robotics subsidiary responsible for licensing and marketing the AuriBot™ – the bacterial robot focused on initially targeting and destroying skull-based cholesteatoma.

For more information on Auricle Solutions, visit its web site at http://www.AuricleSolutions.com.

Contact 

Jason E. Barkeloo – President
+1.513.252.2901
Twitter:  @AuriBot at http://www.twitter.com/AuriBot
http://www.auriclesolutions.com/contact/
info(at)AuricleSolutions.com

About Bacterial Robotics

An early developer in the emerging evolutionary engineering industry, Bacterial Robotics is headquartered in Cincinnati, Ohio (USA).  The Company specializes in identifying markets for developing and deployingBactoBots™ andViruBots™; microscopic organism-based robots that produce, build, sense, and perform functions.

The Company’s products are protected by a proprietary genetics rights management (GeRM™) key system.  The GeRM system is a consumable additive that prevents theBactoBots against theft or release into the environment.  The GeRM enables the Company to gain licensing revenues from the local manufacture and distribution of itsBactoBots.

Once Bacterial Robotics develops a BactoBot, it creates a go-to-market subsidiary to launch the product. Pilus Energy (wastewater-to-value) and Auricle Solutions (tumor eradication) are the current subsidiaries.

For more information on Bacterial Robotics, visit its web site at http://BacterialRobotics.com.

Contact 

Jason E. Barkeloo
CEO
+1.513.252.2901
Twitter:  @BactoBot at http://www.twitter.com/BactoBot
http://www.BacterialRobotics.com/contact/
info(at)BacterialRobotics.com

###

Our Effort

Open Therapeutics is a major backer of open science and open access efforts.

Open Therapeutics freely provides to science, technology, engineering, and math (STEM) scientists, or another other seriously interested persons, intellectual properties (patents, etc.), grant funding, lab equipment, document development tools, and preprint server in a collaboration platform (Therapoid™).

When the researchers advance the intellectual properties, s/he gains ScienceCoins™; a blockchain-based cryptocurrency.